Upsher-Smith launches generic Aromasin

MAPLE GROVE, Minn. — Upsher-Smith Laboratories has introduced its generic of Aromasin (exemestane) tablets. The drug is an aromatase inhibitor indicated as an adjuvant treatment in postmenopausal women with breast cancer than has been treated with tamoxifen.

"We are pleased to offer physicians and patients a cost-effective alternative to Aromasin.” Upsher-Smith president and CEO Rusty Field said. "The addition of exemestane tablets supports our company's ongoing commitment to expanding our product portfolio and making quality, reasonably priced generics available to the most patients possible.”

The drug had U.S. sales of approximately $84 million for the 12 months ended August 31, according to QuintilesIMS data. It is available in 25-mg dosage strength.